Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial

Am J Hematol. 2018 May;93(5):E125-E127. doi: 10.1002/ajh.25062. Epub 2018 Feb 24.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Decitabine / pharmacology*
  • Decitabine / therapeutic use
  • Humans
  • Karyotyping*
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / mortality
  • Monosomy*
  • Progression-Free Survival*
  • Survival Analysis

Substances

  • Decitabine